deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04683003

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)

Sponsor: Shire

Interventions TAK-755
Updated 14 times since 2021 Last updated: Apr 21, 2025 Started: Apr 14, 2021 Primary completion: Mar 16, 2027 Completion: Mar 16, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Thrombotic Thrombocytopenic Purpura (TTP) and is currently actively recruiting participants. Shire leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Nov 2022 · 6 months · monthly snapshot~Nov 2022 – ~May 2023 · 6 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Dec 2023 · 6 months · monthly snapshot~Dec 2023 – ~May 2024 · 5 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded
  1. Sep 2025 — Present [monthly]

    Recruiting PHASE3

  2. May 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  3. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  5. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

Show 9 earlier versions
  1. Dec 2023 — May 2024 [monthly]

    Recruiting PHASE3

  2. Jun 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  3. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  4. Nov 2022 — May 2023 [monthly]

    Recruiting PHASE3

  5. May 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  6. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE3

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  8. Apr 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE3

  9. Jan 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shire
  • Takeda
  • Takeda Development Center Americas, Inc.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .